Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor...

|By:, SA News Editor

Aeterna Zentaris (AEZS +2%) gains today after saying earlier that its oral AKT inhibitor perifosine, when combined with temsirolimus, was well tolerated while treating recurrent or progressive malignant glioma during Phase 1 clinical trials.